X4 Pharmaceuticals (XFOR)

• Market cap: $58.4M
• 1 day: 7.47%
• 5 days: -9.42%
• 1 month: -28.79%
• 3 months: -43.00%
• 6 months: -49.51%
• Year to date: -54.48%
• 1 year: -60.43%
• 5 years: -95.79%
• 10 years: -99.59%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 143

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

310% more call options, than puts

Call options by funds: $550K | Put options by funds: $134K

9% more capital invested

Capital invested by funds: $67.4M [Q3] → $73.2M (+$5.85M) [Q4]

10% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 21

1.23% less ownership

Funds ownership: 59.74% [Q3] → 58.51% (-1.23%) [Q4]

9% less funds holding

Funds holding: 98 [Q3] → 89 (-9) [Q4]

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $1.50 338% upside
• Avg. target: $1.50 338% upside
• High target: $1.50 338% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 22% 1-year accuracy 44 / 198 met price target

338% upside $1.50

Buy Reiterated

7 Feb 2025